Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer by Sosa, Julie A., MD, Balkissoon, Jai, MD, Lu, Shiao-ping, MS, Langecker, Peter, MD, Elisei, Rossella, MD, Jarzab, Barbara, MD, Bal, C.S., MD, Marur, Shanthi, MD, Gramza, Ann, MD, Ondrey, Frank, MD

Get full text

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small... by Garon, Edward B, Neidhart, Jeffrey D, Gabrail, Nashat Y, de Oliveira, Moacyr R, Balkissoon, Jai, Kabbinavar, Fairooz

Get full text

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors by PATTERSON, Dan M, ZWEIFEL, Martin, CHAPLIN, Dai J, PADHANI, Anwar R, RUSTIN, Gordon J. S, MIDDLETON, Mark R, PRICE, Patricia M, FOLKES, Lisa K, STRATFORD, Michael R. L, ROSS, Phil, HALFORD, Sarah, PETERS, Jane, BALKISSOON, Jai

Get full text

Abstract A4: Combretastatin A-4 Phosphate (CA4P) is effective for the treatment of functional pancreatic neuroendocrine tumors (PNETs) in a transgenic mouse model by Yuan, Ziqiang, Zaphiros, Nikolas, Adem, Asha, Etienne, Norvilia, Balkissoon, Jai, Chaplin, Dai, Libutti, Steven K.

Get full text

A randomized Phase II trial of the tumor vascular disrupting agent CA4P by Garon, Edward B, Neidhart, Jeffrey D, Kabbinavar, Fairooz, Gabrail, Nashat Y, Balkissoon, Jai, de Oliveira, Moacyr R

Get full text

Increasing Birth Cohort Screening for Chronic Hepatitis C in a Primary Care Clinic with Panel Management by Balkissoon, Christopher Jai, Hampton, Michelle DeCoux

Get full text

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) by Cogle, Christopher R, Gonzalez, Andres, Pettiford, Leslie, Meacham, Amy, Wise, Elizabeth, Norkin, Maxim, Chaplin, David, Balkissoon, Jai, Hsu, Jack W, Brown, Randy A, Hiemenz, John W, Wingard, John R

Get full text

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate by Ibrahim, Mohamed A, Do, Diana V, Sepah, Yasir J, Shah, Syed M, Van Anden, Elizabeth, Hafiz, Gulnar, Donahue, J Kevin, Rivers, Richard, Balkissoon, Jai, Handa, James T, Campochiaro, Peter A, Nguyen, Quan Dong

Get full text

Abstract B19: Interim safety results of a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (Ca4p) with carboplatin, paclitaxel and bevacizum... by Garon, Edward B., Kabbinavar, Fairooz, Balkissoon, Jai, Lu, Shaio-Ping, Neidhart, James A., Gabrail, Nash, de Oliveira, Moacyr R.

Get full text